Announce initial clinical data for AMT-130

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 25 Oct 2021
Due: 31 Dec 2021
Delivered: 16 Dec 2021

Deadline
Met
Late
Not met
Today

What the company said

“Initial data from the first four enrolled patients in this first-in-human AAV-gene therapy trial are anticipated by year-end 2021.”

SourceuniQure N.V. Form 8-K press release, 2021-10-25
FilingSEC filing index
Deadline as statedby year-end 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-QURE-001784
Cite as https://keptindex.org/c/KI-C-2021-QURE-001784/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced initial 12-month observations for the first four patients in the AMT-130 Phase I/II study on December 16, 2021, meeting the year-end deadline.

A
uniQure N.V. 10-K filed 2022-02-25 Regulatory filing · published 25 Feb 2022 · retrieved 1 Oct 2026 · kept permanently by the SEC
“On December 16, 2021, we announced initial 12-month observations on the first four patients enrolled in the low-dose cohort of the U.S. Phase I/II study.” ✓ confirmed on the page

Market reaction: the shares moved +8.6% against the S&P 500 over the three sessions around the disclosure (24 Feb 2022 to 1 Mar 2022). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1734 days
2 versions

Version 1 · original · stated 25 Oct 2021

Deadline 31 Dec 2021 (“by year-end 2021”) · wording expected
Version 2 · stated 5 May 2026

Deadline 30 Sep 2026 (“in the third quarter”)

“four-year AMT-130 data analysis in the third quarter”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Announce
Deliverable: initial clinical data for AMT-130
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.